{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:13:08Z","timestamp":1793463188764,"version":"4.5.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00018-023-05052-8","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T12:02:14Z","timestamp":1702382534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["SHP2 clinical phenotype, cancer, or RASopathies, can be predicted by mutant conformational propensities"],"prefix":"10.1007","volume":"81","author":[{"given":"Yonglan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wengang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunbum","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-6415","authenticated-orcid":false,"given":"Ruth","family":"Nussinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"issue":"2","key":"5052_CR1","doi-asserted-by":"publisher","first-page":"eabm2059","DOI":"10.1126\/sciadv.abm2059","volume":"8","author":"R Nussinov","year":"2022","unstructured":"Nussinov R, Tsai CJ, Jang H (2022) How can same-gene mutations promote both cancer and developmental disorders? Sci Adv 8(2):eabm2059","journal-title":"Sci Adv"},{"issue":"2","key":"5052_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12551-023-01054-9","volume":"15","author":"R Nussinov","year":"2023","unstructured":"Nussinov R, Yavuz BR, Arici MK, Demirel HC, Zhang M, Liu Y et al (2023) Neurodevelopmental disorders, like cancer, are connected to impaired chromatin remodelers, PI3K\/mTOR, and PAK1-regulated MAPK. Biophys Rev 15(2):163\u2013181","journal-title":"Biophys Rev"},{"issue":"2","key":"5052_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ng1156","volume":"34","author":"M Tartaglia","year":"2003","unstructured":"Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A et al (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34(2):148\u2013150","journal-title":"Nat Genet"},{"issue":"6","key":"5052_CR4","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2003-09-3287","volume":"103","author":"ML Loh","year":"2004","unstructured":"Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH et al (2004) Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103(6):2325\u20132331","journal-title":"Blood"},{"issue":"5","key":"5052_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.tibs.2023.01.005","volume":"48","author":"JE Ladbury","year":"2023","unstructured":"Ladbury JE, Lin CC, Suen KM (2023) Phase separation enhances probability of receptor signalling and drug targeting. Trends Biochem Sci 48(5):428\u2013436","journal-title":"Trends Biochem Sci"},{"key":"5052_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","volume":"62","author":"DL Kerr","year":"2021","unstructured":"Kerr DL, Haderk F, Bivona TG (2021) Allosteric SHP2 inhibitors in cancer: targeting the intersection of RAS, resistance, and the immune microenvironment. Curr Opin Chem Biol 62:1\u201312","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"5052_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1078-0432.CCR-20-2718","volume":"27","author":"C Liu","year":"2021","unstructured":"Liu C, Lu H, Wang H, Loo A, Zhang X, Yang G et al (2021) Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling. Clin Cancer Res 27(1):342\u2013354","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5052_CR8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.cell.2020.09.002","volume":"183","author":"G Zhu","year":"2020","unstructured":"Zhu G, Xie J, Kong W, Xie J, Li Y, Du L et al (2020) Phase separation of disease-associated SHP2 mutants underlies MAPK hyperactivation. Cell 183(2):490-502e18","journal-title":"Cell"},{"issue":"7","key":"5052_CR9","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","volume":"24","author":"DA Ruess","year":"2018","unstructured":"Ruess DA, Heynen GJ, Ciecielski KJ, Ai J, Berninger A, Kabacaoglu D et al (2018) Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase. Nat Med 24(7):954\u2013960","journal-title":"Nat Med"},{"issue":"1","key":"5052_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s42003-021-01969-7","volume":"4","author":"CC Lin","year":"2021","unstructured":"Lin CC, Wieteska L, Suen KM, Kalverda AP, Ahmed Z, Ladbury JE (2021) Grb2 binding induces phosphorylation-independent activation of Shp2. Commun Biol 4(1):437","journal-title":"Commun Biol"},{"key":"5052_CR11","doi-asserted-by":"publisher","first-page":"8859","DOI":"10.1038\/ncomms9859","volume":"6","author":"S Bunda","year":"2015","unstructured":"Bunda S, Burrell K, Heir P, Zeng L, Alamsahebpour A, Kano Y et al (2015) Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat Commun 6:8859","journal-title":"Nat Commun"},{"issue":"1","key":"5052_CR12","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.1038\/s41467-021-26526-y","volume":"12","author":"T Gebregiworgis","year":"2021","unstructured":"Gebregiworgis T, Kano Y, St-Germain J, Radulovich N, Udaskin ML, Mentes A et al (2021) The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nat Commun 12(1):6274","journal-title":"Nat Commun"},{"issue":"16","key":"5052_CR13","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-19-3822","volume":"80","author":"I Valencia-Sama","year":"2020","unstructured":"Valencia-Sama I, Ladumor Y, Kee L, Adderley T, Christopher G, Robinson CM et al (2020) NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma. Cancer Res 80(16):3413\u20133423","journal-title":"Cancer Res"},{"issue":"1","key":"5052_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41467-018-08115-8","volume":"10","author":"Y Kano","year":"2019","unstructured":"Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon BPK, St-Germain J et al (2019) Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nat Commun 10(1):224","journal-title":"Nat Commun"},{"issue":"49","key":"5052_CR15","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1038\/s41388-020-01488-5","volume":"39","author":"H Chen","year":"2020","unstructured":"Chen H, Libring S, Ruddraraju KV, Miao J, Solorio L, Zhang ZY et al (2020) SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer. Oncogene 39(49):7166\u20137180","journal-title":"Oncogene"},{"issue":"2","key":"5052_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10555-008-9126-y","volume":"27","author":"G Chan","year":"2008","unstructured":"Chan G, Kalaitzidis D, Neel BG (2008) The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 27(2):179\u2013192","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"5052_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","volume":"75","author":"J Li","year":"2015","unstructured":"Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T et al (2015) PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 75(3):508\u2013518","journal-title":"Cancer Res"},{"issue":"9","key":"5052_CR18","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/jcmm.12618","volume":"19","author":"J Zhang","year":"2015","unstructured":"Zhang J, Zhang F, Niu R (2015) Functions of Shp2 in cancer. J Cell Mol Med 19(9):2075\u20132083","journal-title":"J Cell Mol Med"},{"issue":"24","key":"5052_CR19","doi-asserted-by":"publisher","first-page":"8816","DOI":"10.1158\/0008-5472.CAN-04-1923","volume":"64","author":"M Bentires-Alj","year":"2004","unstructured":"Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K et al (2004) Activating mutations of the noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64(24):8816\u20138820","journal-title":"Cancer Res"},{"issue":"25","key":"5052_CR20","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1038\/sj.onc.1211019","volume":"27","author":"D Miyamoto","year":"2008","unstructured":"Miyamoto D, Miyamoto M, Takahashi A, Yomogita Y, Higashi H, Kondo S et al (2008) Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 27(25):3508\u20133515","journal-title":"Oncogene"},{"key":"5052_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev.genom.6.080604.162305","volume":"6","author":"M Tartaglia","year":"2005","unstructured":"Tartaglia M, Gelb BD (2005) Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 6:45\u201368","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"4","key":"5052_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nm.2645","volume":"18","author":"N Aceto","year":"2012","unstructured":"Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G et al (2012) Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 18(4):529\u2013537","journal-title":"Nat Med"},{"issue":"5","key":"5052_CR23","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/bloodadvances.2021006242","volume":"6","author":"S Fobare","year":"2022","unstructured":"Fobare S, Kohlschmidt J, Ozer HG, Mrozek K, Nicolet D, Mims AS et al (2022) Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Adv 6(5):1371\u20131380","journal-title":"Blood Adv"},{"issue":"3","key":"5052_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41375-020-0920-z","volume":"35","author":"M Alfayez","year":"2021","unstructured":"Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ et al (2021) The clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691\u2013700","journal-title":"Leukemia"},{"issue":"4","key":"5052_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/74279","volume":"24","author":"TM Saxton","year":"2000","unstructured":"Saxton TM, Ciruna BG, Holmyard D, Kulkarni S, Harpal K, Rossant J et al (2000) The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat Genet 24(4):420\u2013423","journal-title":"Nat Genet"},{"issue":"4","key":"5052_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ng772","volume":"29","author":"M Tartaglia","year":"2001","unstructured":"Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H et al (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29(4):465\u2013468","journal-title":"Nat Genet"},{"issue":"2","key":"5052_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1086\/341528","volume":"71","author":"MC Digilio","year":"2002","unstructured":"Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B et al (2002) Grouping of multiple-lentigines\/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71(2):389\u2013394","journal-title":"Am J Hum Genet"},{"issue":"10","key":"5052_CR28","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.M513068200","volume":"281","author":"MI Kontaridis","year":"2006","unstructured":"Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG (2006) PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 281(10):6785\u20136792","journal-title":"J Biol Chem"},{"issue":"13","key":"5052_CR29","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00018-007-6509-0","volume":"64","author":"T Edouard","year":"2007","unstructured":"Edouard T, Montagner A, Dance M, Conte F, Yart A, Parfait B et al (2007) How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms? Cell Mol Life Sci 64(13):1585\u20131590","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"5052_CR30","first-page":"17","volume":"2","author":"H Zheng","year":"2009","unstructured":"Zheng H, Alter S, Qu CK (2009) SHP-2 tyrosine phosphatase in human diseases. Int J Clin Exp Med 2(1):17\u201325","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"5052_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1073\/pnas.1508535113","volume":"113","author":"X Liu","year":"2016","unstructured":"Liu X, Zheng H, Li X, Wang S, Meyerson HJ, Yang W et al (2016) Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. Proc Natl Acad Sci USA 113(4):984\u2013989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"5052_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5826\/dpc.0801a14","volume":"8","author":"C Colmant","year":"2018","unstructured":"Colmant C, Franck D, Marot L, Matthijs G, Sznajer Y, Blomme S et al (2018) Patient with confirmed LEOPARD syndrome developing multiple melanoma. Dermatol Pract Concept 8(1):59\u201362","journal-title":"Dermatol Pract Concept"},{"issue":"8","key":"5052_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/MPH.0b013e31817588fb","volume":"30","author":"D Laux","year":"2008","unstructured":"Laux D, Kratz C, Sauerbrey A (2008) Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome. J Pediatr Hematol Oncol 30(8):602\u2013604","journal-title":"J Pediatr Hematol Oncol"},{"issue":"25","key":"5052_CR34","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1182\/blood.2019001543","volume":"134","author":"M Bellio","year":"2019","unstructured":"Bellio M, Garcia C, Edouard T, Voisin S, Neel BG, Cabou C et al (2019) Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions. Blood 134(25):2304\u20132317","journal-title":"Blood"},{"key":"5052_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2022.106766","volume":"283","author":"R Nussinov","year":"2022","unstructured":"Nussinov R, Tsai CJ, Jang H (2022) Allostery, and how to define and measure signal transduction. Biophys Chem 283:106766","journal-title":"Biophys Chem"},{"issue":"22","key":"5052_CR36","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1158\/0008-5472.CAN-22-2125","volume":"82","author":"R Nussinov","year":"2022","unstructured":"Nussinov R, Tsai CJ, Jang H (2022) A new view of activating mutations in cancer. Cancer Res 82(22):4114\u20134123","journal-title":"Cancer Res"},{"issue":"11","key":"5052_CR37","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/ng.3420","volume":"47","author":"A Caye","year":"2015","unstructured":"Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O et al (2015) Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet 47(11):1334\u20131340","journal-title":"Nat Genet"},{"issue":"11","key":"5052_CR38","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/hmg\/ddz108","volume":"29","author":"M Motta","year":"2020","unstructured":"Motta M, Sagi-Dain L, Krumbach OHF, Hahn A, Peleg A, German A et al (2020) Activating MRAS mutations cause Noonan syndrome associated with hypertrophic cardiomyopathy. Hum Mol Genet 29(11):1772\u20131783","journal-title":"Hum Mol Genet"},{"issue":"5","key":"5052_CR39","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1021\/acs.jcim.2c01634","volume":"63","author":"S Agajanian","year":"2023","unstructured":"Agajanian S, Alshahrani M, Bai F, Tao P, Verkhivker GM (2023) Exploring and learning the universe of protein allostery using artificial intelligence augmented biophysical and computational approaches. J Chem Inf Model 63(5):1413\u20131428","journal-title":"J Chem Inf Model"},{"issue":"1","key":"5052_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/neuroglia4010001","volume":"4","author":"A Rubio-Casillas","year":"2022","unstructured":"Rubio-Casillas A, Redwan EM, Uversky VN (2022) On the potential therapeutic roles of taurine in autism spectrum disorder. Neuroglia 4(1):1\u201314","journal-title":"Neuroglia"},{"issue":"6","key":"5052_CR41","doi-asserted-by":"publisher","first-page":"104492","DOI":"10.1016\/j.isci.2022.104492","volume":"25","author":"R Nussinov","year":"2022","unstructured":"Nussinov R, Tsai CJ, Jang H (2022) Neurodevelopmental disorders, immunity, and cancer are connected. iScience. 25(6):104492","journal-title":"iScience."},{"issue":"3","key":"5052_CR42","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0002-9440(10)64896-1","volume":"160","author":"I Tomlinson","year":"2002","unstructured":"Tomlinson I, Sasieni P, Bodmer W (2002) How many mutations in a cancer? Am J Pathol 160(3):755\u2013758","journal-title":"Am J Pathol"},{"issue":"1","key":"5052_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1073\/pnas.1421839112","volume":"112","author":"C Tomasetti","year":"2015","unstructured":"Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B (2015) Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci USA 112(1):118\u2013123","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"5052_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1158\/0008-5472.CAN-17-2727","volume":"78","author":"R Nussinov","year":"2018","unstructured":"Nussinov R, Tsai CJ, Jang H (2018) Oncogenic Ras isoforms signaling specificity at the membrane. Cancer Res 78(3):593\u2013602","journal-title":"Cancer Res"},{"issue":"1","key":"5052_CR45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s42003-023-04519-5","volume":"6","author":"BR Yavuz","year":"2023","unstructured":"Yavuz BR, Tsai CJ, Nussinov R, Tuncbag N (2023) Pan-cancer clinical impact of latent drivers from double mutations. Commun Biol 6(1):202","journal-title":"Commun Biol"},{"key":"5052_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.sbi.2021.06.002","volume":"71","author":"GM Verkhivker","year":"2021","unstructured":"Verkhivker GM (2021) Making the invisible visible: toward structural characterization of allosteric states, interaction networks, and allosteric regulatory mechanisms in protein kinases. Curr Opin Struct Biol 71:71\u201378","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"5052_CR47","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1038\/s41467-018-06814-w","volume":"9","author":"RAP Padua","year":"2018","unstructured":"Padua RAP, Sun Y, Marko I, Pitsawong W, Stiller JB, Otten R et al (2018) Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nat Commun 9(1):4507","journal-title":"Nat Commun"},{"issue":"5","key":"5052_CR48","doi-asserted-by":"publisher","first-page":"eaay4458","DOI":"10.1126\/sciadv.aay4458","volume":"6","author":"M Marasco","year":"2020","unstructured":"Marasco M, Berteotti A, Weyershaeuser J, Thorausch N, Sikorska J, Krausze J et al (2020) Molecular mechanism of SHP2 activation by PD-1 stimulation. Sci Adv 6(5):eaay4458","journal-title":"Sci Adv"},{"issue":"15","key":"5052_CR49","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1021\/acs.biochem.5b01287","volume":"55","author":"JR LaRochelle","year":"2016","unstructured":"LaRochelle JR, Fodor M, Xu X, Durzynska I, Fan L, Stams T et al (2016) Structural and functional consequences of three cancer-associated mutations of the oncogenic phosphatase SHP2. Biochemistry 55(15):2269\u20132277","journal-title":"Biochemistry"},{"issue":"12","key":"5052_CR50","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.tips.2019.10.003","volume":"40","author":"R Nussinov","year":"2019","unstructured":"Nussinov R, Tsai C-J, Jang H (2019) Why are some driver mutations rare? Trends Pharmacol Sci 40(12):919\u2013929","journal-title":"Trends Pharmacol Sci"},{"issue":"17","key":"5052_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167695","volume":"434","author":"P Grudzien","year":"2022","unstructured":"Grudzien P, Jang H, Leschinsky N, Nussinov R, Gaponenko V (2022) Conformational dynamics allows sampling of an \u201cactive-like\u201d state by oncogenic K-Ras-GDP. J Mol Biol 434(17):167695","journal-title":"J Mol Biol"},{"issue":"2","key":"5052_CR52","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1086\/499925","volume":"78","author":"M Tartaglia","year":"2006","unstructured":"Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V et al (2006) Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78(2):279\u2013290","journal-title":"Am J Hum Genet"},{"issue":"35","key":"5052_CR53","doi-asserted-by":"publisher","first-page":"30984","DOI":"10.1074\/jbc.M504699200","volume":"280","author":"H Keilhack","year":"2005","unstructured":"Keilhack H, David FS, McGregor M, Cantley LC, Neel BG (2005) Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem. 280(35):30984\u201330993","journal-title":"J Biol Chem."},{"issue":"2","key":"5052_CR54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ccr.2005.01.010","volume":"7","author":"MG Mohi","year":"2005","unstructured":"Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S et al (2005) Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7(2):179\u2013191","journal-title":"Cancer Cell"},{"issue":"1","key":"5052_CR55","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1038\/s41467-020-19669-x","volume":"11","author":"V Pejaver","year":"2020","unstructured":"Pejaver V, Urresti J, Lugo-Martinez J, Pagel KA, Lin GN, Nam HJ et al (2020) Inferring the molecular and phenotypic impact of amino acid variants with MutPred2. Nat Commun 11(1):5918","journal-title":"Nat Commun"},{"issue":"4","key":"5052_CR56","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.bbrc.2015.12.117","volume":"469","author":"S Noda","year":"2016","unstructured":"Noda S, Takahashi A, Hayashi T, Tanuma S, Hatakeyama M (2016) Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling. Biochem Biophys Res Commun 469(4):1133\u20131139","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"5052_CR57","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/jmg.40.9.704","volume":"40","author":"A Sarkozy","year":"2003","unstructured":"Sarkozy A, Conti E, Seripa D, Digilio MC, Grifone N, Tandoi C et al (2003) Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. J Med Genet 40(9):704\u2013708","journal-title":"J Med Genet"},{"issue":"6","key":"5052_CR58","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1086\/340847","volume":"70","author":"M Tartaglia","year":"2002","unstructured":"Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I et al (2002) PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype\u2013phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70(6):1555\u20131563","journal-title":"Am J Hum Genet"},{"issue":"2","key":"5052_CR59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/sj.ejhg.5200935","volume":"11","author":"L Musante","year":"2003","unstructured":"Musante L, Kehl HG, Majewski F, Meinecke P, Schweiger S, Gillessen-Kaesbach G et al (2003) Spectrum of mutations in PTPN11 and genotype\u2013phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet 11(2):201\u2013206","journal-title":"Eur J Hum Genet"},{"issue":"11\u201312","key":"5052_CR60","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s10038-008-0343-6","volume":"53","author":"JM Ko","year":"2008","unstructured":"Ko JM, Kim JM, Kim GH, Yoo HW (2008) PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet 53(11\u201312):999\u20131006","journal-title":"J Hum Genet"},{"issue":"8","key":"5052_CR61","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1210\/jcem.87.8.8694","volume":"87","author":"K Kosaki","year":"2002","unstructured":"Kosaki K, Suzuki T, Muroya K, Hasegawa T, Sato S, Matsuo N et al (2002) PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J Clin Endocrinol Metab 87(8):3529\u20133533","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5052_CR62","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/humu.10129","volume":"20","author":"M Maheshwari","year":"2002","unstructured":"Maheshwari M, Belmont J, Fernbach S, Ho T, Molinari L, Yakub I et al (2002) PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13. Hum Mutat 20(4):298\u2013304","journal-title":"Hum Mutat"},{"issue":"1","key":"5052_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.ejhg.5200915","volume":"11","author":"E Schollen","year":"2003","unstructured":"Schollen E, Matthijs G, Gewillig M, Fryns JP, Legius E (2003) PTPN11 mutation in a large family with Noonan syndrome and dizygous twinning. Eur J Hum Genet 11(1):85\u201388","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"5052_CR64","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/humu.23175","volume":"38","author":"L Pannone","year":"2017","unstructured":"Pannone L, Bocchinfuso G, Flex E, Rossi C, Baldassarre G, Lissewski C et al (2017) Structural, functional, and clinical characterization of a novel PTPN11 mutation cluster underlying noonan syndrome. Hum Mutat 38(4):451\u2013459","journal-title":"Hum Mutat"},{"issue":"5","key":"5052_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2003.013466","volume":"41","author":"A Sarkozy","year":"2004","unstructured":"Sarkozy A, Conti E, Digilio MC, Marino B, Morini E, Pacileo G et al (2004) Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. J Med Genet 41(5):e68","journal-title":"J Med Genet"},{"issue":"11","key":"5052_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.021451","volume":"41","author":"B Keren","year":"2004","unstructured":"Keren B, Hadchouel A, Saba S, Sznajer Y, Bonneau D, Leheup B et al (2004) PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. J Med Genet 41(11):e117","journal-title":"J Med Genet"},{"issue":"3","key":"5052_CR67","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.mph.0000199590.21797.0b","volume":"28","author":"C Ucar","year":"2006","unstructured":"Ucar C, Calyskan U, Martini S, Heinritz W (2006) Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive). J Pediatr Hematol Oncol 28(3):123\u2013125","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"5052_CR68","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ajmg.a.30270","volume":"130A","author":"DR Bertola","year":"2004","unstructured":"Bertola DR, Pereira AC, de Oliveira PS, Kim CA, Krieger JE (2004) Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation. Am J Med Genet A 130A(4):378\u2013383","journal-title":"Am J Med Genet A"},{"issue":"9","key":"5052_CR69","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/ajmg.a.36620","volume":"164A","author":"JJ Edwards","year":"2014","unstructured":"Edwards JJ, Martinelli S, Pannone L, Lo IF, Shi L, Edelmann L et al (2014) A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype. Am J Med Genet A 164A(9):2351\u20132355","journal-title":"Am J Med Genet A"},{"issue":"7\u20138","key":"5052_CR70","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00431-003-1227-6","volume":"162","author":"T Kondoh","year":"2003","unstructured":"Kondoh T, Ishii E, Aoki Y, Shimizu T, Zaitsu M, Matsubara Y et al (2003) Noonan syndrome with leukaemoid reaction and overproduction of catecholamines: a case report. Eur J Pediatr 162(7\u20138):548\u2013549","journal-title":"Eur J Pediatr"},{"issue":"3","key":"5052_CR71","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ajmg.a.30813","volume":"136","author":"DR Bertola","year":"2005","unstructured":"Bertola DR, Pereira AC, Passetti F, de Oliveira PS, Messiaen L, Gelb BD et al (2005) Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. Am J Med Genet A 136(3):242\u2013245","journal-title":"Am J Med Genet A"},{"issue":"8","key":"5052_CR72","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00431-005-1679-y","volume":"164","author":"K Takahashi","year":"2005","unstructured":"Takahashi K, Kogaki S, Kurotobi S, Nasuno S, Ohta M, Okabe H et al (2005) A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy. Eur J Pediatr 164(8):497\u2013500","journal-title":"Eur J Pediatr"},{"issue":"11","key":"5052_CR73","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00431-006-0163-7","volume":"165","author":"MC Digilio","year":"2006","unstructured":"Digilio MC, Sarkozy A, Pacileo G, Limongelli G, Marino B, Dallapiccola B (2006) PTPN11 gene mutations: linking the Gln510Glu mutation to the \u201cLEOPARD syndrome phenotype.\u201d Eur J Pediatr 165(11):803\u2013805","journal-title":"Eur J Pediatr"},{"issue":"4","key":"5052_CR74","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/ajmg.a.30281","volume":"130A","author":"R Yoshida","year":"2004","unstructured":"Yoshida R, Nagai T, Hasegawa T, Kinoshita E, Tanaka T, Ogata T (2004) Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome. Am J Med Genet A 130A(4):432\u2013434","journal-title":"Am J Med Genet A"},{"issue":"1","key":"5052_CR75","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10038-004-0212-x","volume":"50","author":"K Kalidas","year":"2005","unstructured":"Kalidas K, Shaw AC, Crosby AH, Newbury-Ecob R, Greenhalgh L, Temple IK et al (2005) Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11. J Hum Genet 50(1):21\u201325","journal-title":"J Hum Genet"},{"issue":"15","key":"5052_CR76","doi-asserted-by":"publisher","first-page":"10472","DOI":"10.1074\/jbc.M113.450023","volume":"288","author":"ZH Yu","year":"2013","unstructured":"Yu ZH, Xu J, Walls CD, Chen L, Zhang S, Zhang R et al (2013) Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J Biol Chem 288(15):10472\u201310482","journal-title":"J Biol Chem"},{"issue":"3","key":"5052_CR77","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0969-2126(98)00027-6","volume":"6","author":"D Barford","year":"1998","unstructured":"Barford D, Neel BG (1998) Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 6(3):249\u2013254","journal-title":"Structure"},{"key":"5052_CR78","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.csbj.2021.04.040","volume":"19","author":"M Marasco","year":"2021","unstructured":"Marasco M, Kirkpatrick J, Nanna V, Sikorska J, Carlomagno T (2021) Phosphotyrosine couples peptide binding and SHP2 activation via a dynamic allosteric network. Comput Struct Biotechnol J 19:2398\u20132415","journal-title":"Comput Struct Biotechnol J"},{"issue":"17","key":"5052_CR79","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.febslet.2012.04.054","volume":"586","author":"BA Liu","year":"2012","unstructured":"Liu BA, Engelmann BW, Nash PD (2012) The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction. FEBS Lett 586(17):2597\u20132605","journal-title":"FEBS Lett"},{"issue":"21","key":"5052_CR80","doi-asserted-by":"publisher","first-page":"15973","DOI":"10.1021\/acs.jmedchem.1c01371","volume":"64","author":"S Bobone","year":"2021","unstructured":"Bobone S, Pannone L, Biondi B, Solman M, Flex E, Canale VC et al (2021) Targeting oncogenic src homology 2 domain-containing phosphatase 2 (SHP2) by inhibiting its protein\u2013protein interactions. J Med Chem 64(21):15973\u201315990","journal-title":"J Med Chem"},{"issue":"17","key":"5052_CR81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025107118","volume":"118","author":"M Anselmi","year":"2021","unstructured":"Anselmi M, Hub JS (2021) The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation. Proc Natl Acad Sci USA 118(17):e2025107118","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"5052_CR82","doi-asserted-by":"publisher","first-page":"18530","DOI":"10.1038\/s41598-020-75409-7","volume":"10","author":"M Anselmi","year":"2020","unstructured":"Anselmi M, Hub JS (2020) An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase. Sci Rep 10(1):18530","journal-title":"Sci Rep"},{"key":"5052_CR83","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1016\/j.csbj.2021.10.041","volume":"19","author":"P Calligari","year":"2021","unstructured":"Calligari P, Santucci V, Stella L, Bocchinfuso G (2021) Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state. Comput Struct Biotechnol J 19:6125\u20136139","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"5052_CR84","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0959-440X(02)00290-7","volume":"12","author":"WA Lim","year":"2002","unstructured":"Lim WA (2002) The modular logic of signaling proteins: building allosteric switches from simple binding domains. Curr Opin Struct Biol 12(1):61\u201368","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"5052_CR85","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","volume":"9","author":"JR LaRochelle","year":"2018","unstructured":"LaRochelle JR, Fodor M, Vemulapalli V, Mohseni M, Wang P, Stams T et al (2018) Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. Nat Commun 9(1):4508","journal-title":"Nat Commun"},{"issue":"11","key":"5052_CR86","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1158\/0008-5472.CAN-21-0548","volume":"82","author":"A Pfeiffer","year":"2022","unstructured":"Pfeiffer A, Franciosa G, Locard-Paulet M, Piga I, Reckzeh K, Vemulapalli V et al (2022) Phosphorylation of SHP2 at Tyr62 enables acquired resistance to SHP2 allosteric inhibitors in FLT3-ITD-driven AML. Cancer Res 82(11):2141\u20132155","journal-title":"Cancer Res"},{"key":"5052_CR87","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/bs.acr.2021.07.002","volume":"153","author":"YT Chou","year":"2022","unstructured":"Chou YT, Bivona TG (2022) Inhibition of SHP2 as an approach to block RAS-driven cancers. Adv Cancer Res 153:205\u2013236","journal-title":"Adv Cancer Res"},{"issue":"7610","key":"5052_CR88","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nature18621","volume":"535","author":"YN Chen","year":"2016","unstructured":"Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG et al (2016) Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535(7610):148\u2013152","journal-title":"Nature"},{"key":"5052_CR89","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.sbi.2015.01.004","volume":"32","author":"R Nussinov","year":"2015","unstructured":"Nussinov R, Tsai CJ (2015) \u201cLatent drivers\u201d expand the cancer mutational landscape. Curr Opin Struct Biol 32:25\u201332","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"5052_CR90","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12551-018-0496-2","volume":"11","author":"R Nussinov","year":"2019","unstructured":"Nussinov R, Jang H, Tsai C-J, Cheng F (2019) Precision medicine review: rare driver mutations and their biophysical classification. Biophys Rev 11(1):5\u201319","journal-title":"Biophys Rev"},{"issue":"4","key":"5052_CR91","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr","year":"1971","unstructured":"Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820\u2013823","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"5052_CR92","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/bjc.1969.41","volume":"23","author":"D Ashley","year":"1969","unstructured":"Ashley D (1969) The two\" hit\" and multiple\" hit\" theories of carcinogenesis. Br J Cancer 23(2):313","journal-title":"Br J Cancer"},{"issue":"1","key":"5052_CR93","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/bjc.1953.8","volume":"7","author":"CO Nordling","year":"1953","unstructured":"Nordling CO (1953) A new theory on cancer-inducing mechanism. Br J Cancer 7(1):68\u201372","journal-title":"Br J Cancer"},{"issue":"12","key":"5052_CR94","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.celrep.2015.08.037","volume":"12","author":"A Prahallad","year":"2015","unstructured":"Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L et al (2015) PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs. Cell Rep 12(12):1978\u20131985","journal-title":"Cell Rep"},{"issue":"3","key":"5052_CR95","doi-asserted-by":"publisher","first-page":"265","DOI":"10.18632\/oncotarget.27435","volume":"11","author":"H Lu","year":"2020","unstructured":"Lu H, Liu C, Huynh H, Le TBU, LaMarche MJ, Mohseni M et al (2020) Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. Oncotarget 11(3):265","journal-title":"Oncotarget"},{"issue":"1","key":"5052_CR96","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","volume":"26","author":"TA Ahmed","year":"2019","unstructured":"Ahmed TA, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson SA et al (2019) SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors. Cell Rep 26(1):65-78e5","journal-title":"Cell Rep"},{"issue":"20","key":"5052_CR97","doi-asserted-by":"publisher","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","volume":"63","author":"X Yuan","year":"2020","unstructured":"Yuan X, Bu H, Zhou J, Yang CY, Zhang H (2020) Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application. J Med Chem 63(20):11368\u201311396","journal-title":"J Med Chem"},{"issue":"10","key":"5052_CR98","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-18-0915","volume":"8","author":"P Torres-Ayuso","year":"2018","unstructured":"Torres-Ayuso P, Brognard J (2018) Shipping out MEK inhibitor resistance with SHP2 inhibitors. Cancer Discov 8(10):1210\u20131212","journal-title":"Cancer Discov"},{"issue":"4","key":"5052_CR99","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/cells8040316","volume":"8","author":"ML Martin-Fernandez","year":"2019","unstructured":"Martin-Fernandez ML, Clarke DT, Roberts SK, Zanetti-Domingues LC, Gervasio FL (2019) Structure and dynamics of the EGF receptor as revealed by experiments and simulations and its relevance to non-small cell lung cancer. Cells 8(4):316","journal-title":"Cells"},{"issue":"12","key":"5052_CR100","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd.2018.201","volume":"17","author":"A Mullard","year":"2018","unstructured":"Mullard A (2018) Phosphatases start shedding their stigma of undruggability. Nat Rev Drug Discov 17(12):847\u2013849","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"5052_CR101","doi-asserted-by":"publisher","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","volume":"63","author":"MJ LaMarche","year":"2020","unstructured":"LaMarche MJ, Acker M, Argintaru A, Bauer D, Boisclair J, Chan H et al (2020) Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer. J Med Chem 63(22):13578\u201313594","journal-title":"J Med Chem"},{"key":"5052_CR102","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0959-8049(20)31089-3","volume":"138","author":"J Bendell","year":"2020","unstructured":"Bendell J, Ulahannan S, Koczywas M, Brahmer J, Capasso A, Eckhardt SG et al (2020) Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b\/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. Eur J Cancer 138:S8\u2013S9","journal-title":"Eur J Cancer"},{"issue":"17","key":"5052_CR103","doi-asserted-by":"publisher","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","volume":"59","author":"J Garcia Fortanet","year":"2016","unstructured":"Garcia Fortanet J, Chen CH, Chen YN, Chen Z, Deng Z, Firestone B et al (2016) Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor. J Med Chem 59(17):7773\u20137782","journal-title":"J Med Chem"},{"issue":"3","key":"5052_CR104","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1021\/acschembio.7b00980","volume":"13","author":"M Fodor","year":"2018","unstructured":"Fodor M, Price E, Wang P, Lu H, Argintaru A, Chen Z et al (2018) Dual allosteric inhibition of SHP2 phosphatase. ACS Chem Biol 13(3):647\u2013656","journal-title":"ACS Chem Biol"},{"issue":"9","key":"5052_CR105","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","volume":"20","author":"RJ Nichols","year":"2018","unstructured":"Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D et al (2018) RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol 20(9):1064\u20131073","journal-title":"Nat Cell Biol"},{"issue":"3","key":"5052_CR106","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/bjc.2017.421","volume":"118","author":"Z Hassan","year":"2018","unstructured":"Hassan Z, Schneeweis C, Wirth M, Veltkamp C, Dantes Z, Feuerecker B et al (2018) MTOR inhibitor-based combination therapies for pancreatic cancer. Br J Cancer 118(3):366\u2013377","journal-title":"Br J Cancer"},{"issue":"7647","key":"5052_CR107","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P et al (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543(7647):733\u2013737","journal-title":"Nature"},{"issue":"4","key":"5052_CR108","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H et al (2019) Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36(4):431-43e5","journal-title":"Cancer Cell"},{"key":"5052_CR109","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1016\/j.csbj.2022.08.014","volume":"20","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang M, Tsai CJ, Jang H, Nussinov R (2022) Allosteric regulation of autoinhibition and activation of c-Abl. Comput Struct Biotechnol J 20:4257\u20134270","journal-title":"Comput Struct Biotechnol J"},{"issue":"7928","key":"5052_CR110","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41586-022-05213-y","volume":"609","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Fan Q, Luo X, Lou K, Weiss WA, Shokat KM (2022) Brain-restricted mTOR inhibition with binary pharmacology. Nature 609(7928):822\u2013828","journal-title":"Nature"},{"issue":"6624","key":"5052_CR111","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.abl5829","volume":"378","author":"K Lou","year":"2022","unstructured":"Lou K, Wassarman DR, Yang T, Paung Y, Zhang Z, O\u2019Loughlin TA et al (2022) IFITM proteins assist cellular uptake of diverse linked chemotypes. Science 378(6624):1097\u20131104","journal-title":"Science"},{"issue":"2","key":"5052_CR112","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD et al (2018) An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(2):400-16e11","journal-title":"Cell"},{"issue":"5","key":"5052_CR113","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401\u2013404","journal-title":"Cancer Discov"},{"issue":"8","key":"5052_CR114","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"F Andr\u00e9","year":"2017","unstructured":"Consortium APG, Consortium APG, Andr\u00e9 F, Arnedos M, Baras AS, Baselga J et al (2017) AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7(8):818\u2013831","journal-title":"Cancer Discov."},{"issue":"16","key":"5052_CR115","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","volume":"26","author":"JC Phillips","year":"2005","unstructured":"Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E et al (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26(16):1781\u20131802","journal-title":"J Comput Chem"},{"issue":"10","key":"5052_CR116","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks BR, Brooks CL 3rd, Mackerell AD Jr, Nilsson L, Petrella RJ, Roux B et al (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30(10):1545\u20131614","journal-title":"J Comput Chem"},{"issue":"1","key":"5052_CR117","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL et al (2017) CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat Methods 14(1):71\u201373","journal-title":"Nat Methods"},{"issue":"23","key":"5052_CR118","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1021\/jp101759q","volume":"114","author":"JB Klauda","year":"2010","unstructured":"Klauda JB, Venable RM, Freites JA, O\u2019Connor JW, Tobias DJ, Mondragon-Ramirez C et al (2010) Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J Phys Chem B 114(23):7830\u20137843","journal-title":"J Phys Chem B"},{"issue":"7","key":"5052_CR119","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.str.2021.02.005","volume":"29","author":"M Zhang","year":"2021","unstructured":"Zhang M, Jang H, Li Z, Sacks DB, Nussinov R (2021) B-Raf autoinhibition in the presence and absence of 14-3-3. Structure 29(7):768\u201377 e2","journal-title":"Structure"},{"key":"5052_CR120","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1016\/j.csbj.2021.06.007","volume":"19","author":"RC Maloney","year":"2021","unstructured":"Maloney RC, Zhang M, Jang H, Nussinov R (2021) The mechanism of activation of monomeric B-Raf V600E. Comput Struct Biotechnol J 19:3349\u20133363","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"5052_CR121","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1039\/C8SC04498H","volume":"10","author":"M Zhang","year":"2019","unstructured":"Zhang M, Jang H, Nussinov R (2019) The mechanism of PI3K\u03b1 activation at the atomic level. Chem Sci 10(12):3671\u20133680","journal-title":"Chem Sci"},{"issue":"5","key":"5052_CR122","doi-asserted-by":"publisher","first-page":"102438","DOI":"10.1016\/j.isci.2021.102438","volume":"24","author":"H Jang","year":"2021","unstructured":"Jang H, Smith IN, Eng C, Nussinov R (2021) The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane. iScience. 24(5):102438","journal-title":"iScience."},{"issue":"12","key":"5052_CR123","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.bpj.2022.05.030","volume":"121","author":"Y Liu","year":"2022","unstructured":"Liu Y, Jang H, Zhang M, Tsai CJ, Maloney R, Nussinov R (2022) The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia. Biophys J 121(12):2251\u20132265","journal-title":"Biophys J"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-05052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-023-05052-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-05052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T12:04:45Z","timestamp":1702382685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-023-05052-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5052"],"URL":"https:\/\/doi.org\/10.1007\/s00018-023-05052-8","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"5"}}